Previous 10 | Next 10 |
Invitae press release ( NYSE: NVTA ): Q3 GAAP EPS of -$1.27 misses by $0.43 . Revenue of $133.54M (+16.7% Y/Y) beats by $2.16M . GAAP gross margin was 12.4%. Non-GAAP gross margin was 45.9% as compared with 40.1% in the second quarter of 2022 and 35.6% in the t...
Invitae Reports Third Quarter 2022 Financial Results PR Newswire — Continued to execute against realignment plan and portfolio optimization initiatives — — Reported revenue of $133.5 million , a 16.7% YoY increase — ...
Invitae ( NYSE: NVTA ) is scheduled to announce Q3 earnings results on Tuesday, November 8th, after market close. The consensus EPS Estimate is -$0.63 (+22.2% Y/Y) and the consensus Revenue Estimate is $131.38M (+14.8% Y/Y). Over the last 2 years, NVTA has beaten EPS...
Summary GH's aberrant trading pattern after its Q3 earnings release on Friday mirrors two conflicting trends arising from the company's unique market position. A new paradigm in the gene testing market is now emphasizing clearer paths to profitability, contradicting GH's spending ...
Invitae (NYSE: NVTA) is a small-cap stock with huge potential in the genetic testing market. The company makes money from providing testing services that can check for rare diseases, hereditary cancer, and other conditions that someone may be susceptible to based on their genes. Its...
Summary VCYT exceeded investors' expectations, coupling solid revenue growth with improved profitability. Unique international exposure offers revenue tailwinds as Europe accelerates gene diagnostic testing adoption. In view of the probability that the political and regulatory...
Invitae study shows therapy informed by genetic testing reduces seizures in some patients with epilepsy PR Newswire – Results support universal genetic testing in all diagnosed patients with epilepsy to potentially improve health outcomes – SAN FRAN...
Summary The FDA is working with congress to extend its regulatory arm over the gene testing market. Veracyte's products are marketed as LDTs and are not approved by the FDA. Regulatory risk weighs against Veracyte's relatively low cash burn and robust balance sheet, underpinni...
Invitae to Present Data at the American Society of Human Genetics Annual Meeting Furthering the Understanding of Variants of Uncertain Significance in Underrepresented Populations PR Newswire – Presentations provide additional insights into the critical importance...
According to data compiled by S&P Global Market Intelligence , genetics testing company Invitae 's (NYSE: NVTA) stock was up 6% in price week to date as of Friday before market open. Investors reacted quite positively to news of a new company partnership with a heavy hitter ...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...